Back to Search Start Over

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria ‐ a systematic review for the EAACI Biologicals Guidelines

Authors :
Knut Brockow
Pablo Alonso-Coello
Margarita Posso
Thomas Eiwegger
Oscar Palomares
Jessica Beltran
Tomas Chivato
Graham S. Ogg
Marek Jutel
Emma Guttman-Yassky
Ivan Solà
Carlos Canelo-Aybar
Peck Y. Ong
Ioana Agache
Marcus Maurer
Ana Pereira
Jürgen Schwarze
Jan Gutermuth
Kilian Eyerich
Mübeccel Akdis
Claudio Rocha
Cezmi A. Akdis
Yang Song
Liam O'Mahony
Thomas Werfel
Ana Giménez-Arnau
Stefano Del Giacco
Artificial Intelligence supported Modelling in clinical Sciences
Gerontology
Skin function and permeability
Dermatology
Source :
Agache, I, Rocha, C, Pereira, A, Song, Y, Alonso-coello, P, Solà, I, Beltran, J, Posso, M, Akdis, C, Akdis, M, Brockow, K, Chivato, T, Del Giacco, S, Eiwegger, T, Eyerich, K, Giménez-arnau, A, Gutermuth, J, Guttman-yassky, E, Maurer, M, Ogg, G, Ong, P, O’mahony, L, Schwarze, J, Werfel, T, Canelo-aybar, C, Palomares, O & Jutel, M 2020, ' Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria - a systematic review for the EAACI Biologicals Guidelines ', Allergy . https://doi.org/10.1111/all.14547, ALLERGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, Fundacion Sancho el Sabio Fundazioa (FSS)
Publication Year :
2020

Abstract

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25), and the itch severity score (ISS)7 (MD -2.15; 95% CI -3.2 to -1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD -2.01; 95%CI -3.22 to -0.81) and decreases (moderate certainty) rescue medication use (MD -1.68; 95%CI -2.95 to -0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5) and decreases (moderate certainty) rescue medication use (MD -2.04; 95%CI -3.19 to -0.88) and drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).

Details

Language :
English
ISSN :
01054538
Database :
OpenAIRE
Journal :
Agache, I, Rocha, C, Pereira, A, Song, Y, Alonso-coello, P, Solà, I, Beltran, J, Posso, M, Akdis, C, Akdis, M, Brockow, K, Chivato, T, Del Giacco, S, Eiwegger, T, Eyerich, K, Giménez-arnau, A, Gutermuth, J, Guttman-yassky, E, Maurer, M, Ogg, G, Ong, P, O’mahony, L, Schwarze, J, Werfel, T, Canelo-aybar, C, Palomares, O & Jutel, M 2020, ' Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria - a systematic review for the EAACI Biologicals Guidelines ', Allergy . https://doi.org/10.1111/all.14547, ALLERGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, Fundacion Sancho el Sabio Fundazioa (FSS)
Accession number :
edsair.doi.dedup.....9e7c579a5a794a5e21fc4b8622648fdd